ProQR Therapeutics N.V.
PRQR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $182 | $129 | $209 |
| - Cash | $107 | $120 | $132 | $149 |
| + Debt | $10 | $17 | $17 | $17 |
| Enterprise Value | – | $79 | $14 | $77 |
| Revenue | $3 | $4 | $5 | $4 |
| % Growth | -23.6% | -15.5% | 4.9% | – |
| Gross Profit | $3 | $4 | $5 | $4 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$10 | -$12 | -$10 | -$6 |
| % Margin | -354.5% | -303.2% | -224.3% | -135.2% |
| Net Income | -$11 | -$12 | -$10 | -$9 |
| % Margin | -377.6% | -319.1% | -223% | -216% |
| EPS Diluted | -0.1 | -0.12 | -0.1 | -0.11 |
| % Growth | 16.7% | -20% | 9.1% | – |
| Operating Cash Flow | -$12 | -$11 | -$16 | -$9 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$12 | -$12 | -$16 | -$9 |